Sanofi Still Needs Fix For Adverse Event Reporting As FDA Seeks Retrospective Study, Pinches Accenture
Executive Summary
FDA's warning letter to Sanofi-Aventis US over the firm's failure to resolve problems that have delayed adverse event reporting shows the agency is emphasizing the issue in its compliance efforts – and becoming more pointed in its requests for fixes.